Navigation Links
Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Date:2/7/2011

ld like to join "Optimer's Conference Call."  The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.  Please connect to Optimer's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.  

About Clostridium difficile Infection (CDI)Clostridium difficile infection, commonly referred to as "C. difficile" or "c-diff", has become a significant medical problem in hospitals, long-term care facilities, and in the community and is estimated to afflict more than 700,000 people each year in the U.S.  It is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, thus allowing C. difficile bacteria to flourish and produce toxins.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the latter being the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of the CDI treatment.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and fluoroquinolones), older age (over 65) and exposure to emerging hyper-virulent strains (BI/NAP1/027, 078, 001) of C. difficile. The increasing incidence of CDI, along with higher rates of both treatment failures and recurrences with current therapies have resulted in greater awareness and concern about CDI among medical prof
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... WASHINGTON , March 27, 2015 ... - The biopharmaceutical industry comes out on top as ... in a new report  from ndp│analytics. According to ... and development (R&D) investment over the last decade, accounting ... 2000-2012. A Short Video on ...
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today ... at 1802 South First St. in the Temple Medical and ... City of Temple to receive funding for ... Texas Veterans Health Care System, the new facility will enable ... biotechnology and life science companies. ...
(Date:3/27/2015)... , March 27, 2015 A new report ... Latin America – Chile , ... are top targets for IVD firms.  The healthcare research ... heavily into IVD strategies for the Latin American continent with ... support globally distributed supply operations. However, the country,s regional economic ...
Breaking Medicine Technology:Week in Review: The Latest from PhRMA 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
... SAN DIEGO, Nov. 16 CareFusion (NYSE: ... announced a Web-based application that provides hospitals with on-demand ... costs. , The CareFusion Knowledge Portal is a remotely ... information dashboard to review metrics and actionable data directly ...
... Nov. 16 Personalized Pharmaceutical Systems (PPS) today announced ... Viropharma Incorporated. , PPS is a clinical trial ... technology in phenomics to help drug companies identify the ... help patients get the right drug the first time. ...
Cached Medicine Technology:CareFusion Launches Knowledge Portal to Provide Actionable Information Across Product Platforms 2CareFusion Launches Knowledge Portal to Provide Actionable Information Across Product Platforms 3Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated 2
(Date:3/28/2015)... 2015 Take a bite of warm, ... action. Acids tumble into the stomach, ready to break ... structure lets these acids run amok, triggering a burning ... symptom. More than 60 million Americans have heartburn at ... heartburn starts, and how it can be stopped. , ...
(Date:3/28/2015)... 2015 The California-based leading wig brand ... customer shopping on UniWigs during the Easter Holidays from ... big promotion on April Fools’ Day. , As the ... around the corner. Easter Festival, with religious origins to ... major holiday after Christmas. The best wig provider, UniWigs, ...
(Date:3/28/2015)... 2015 An article in Fortune on ... prove critical to organizations that deal with PCI (Payment ... of data security, is worsening . Using numbers ... every major category out of the twelve measured improved, ... all the craziness that has gone on in the ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... experiences re-injury, according to research presented today at the ... Specialty Day. The study examined the long term success ... , “We examined survey data from 242 patients ... lead author Justin P. Roe, MBBS, FRACS, from North ...
(Date:3/28/2015)... Early surgery may not be the best ... injuries, according to new research from Tripler Army Medical ... Society for Sports Medicine’s ( AOSSM ) Specialty Day, ... was not performed. , The final study group focused ... 17 receiving non-surgical therapy. Of the non-surgery group, 8 ...
Breaking Medicine News(10 mins):Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2
... medication and reduce risk of ... medication errors, ... move to continually improve patient safety,and staff efficiency, Omnicell, Inc. (Nasdaq: ... facilities, and Grant Regional Health,Center, a leading healthcare provider, today announced ...
... the,appointment of Bryan R. Rogers as President of HCA,s ... Jan. 1, 2008. Rogers replaces Tom,May who recently announced ... will have responsibility for,operations in Nevada, California and Alaska, ... with annual net revenues of,$2.5 billion. He currently ...
... Lead Life Insurance Wholesaling to Company,s Retail Distribution ... Kahal has joined AXA,Equitable as National Sales Manager ... CT. The announcement was made,today by Jamie Shepherdson, ... and annuity wholesale distribution organization. Mr. Kahal,will report ...
... Researchers at the American University of ... that administering a lidocaine lollipop as a single-agent ... endoscopy procedure eliminated the need for sedation in ... in the October issue of Gastrointestinal Endoscopy, the ...
... who couple classroom courses with behind-the-wheel training can significantly ... in the latest issue of The Journal of ... A recent study spearheaded by Yale University,s Richard Marottoli ... underwent eight hours of classroom instruction and two hours ...
... Global Med Technologies(R),Inc. (OTC Bulletin Board: GLOB), ... that it will report its,third quarter results on ... Company will host a conference call at 4:30 ... http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO ) Conference Call Details: ...
Cached Medicine News:Health News:Grant Regional Health Center Increases Patient Safety and Pharmacy Efficiency with Omnicell Medication Use Systems 2Health News:Grant Regional Health Center Increases Patient Safety and Pharmacy Efficiency with Omnicell Medication Use Systems 3Health News:Bryan R. Rogers Appointed President of Far West Division 2Health News:David Kahal Joins AXA Equitable as National Sales Manager 2Health News:Patients may have sweet and effective way to prepare for upper GI endoscopy: an anesthetic lollipop 2Health News:Patients may have sweet and effective way to prepare for upper GI endoscopy: an anesthetic lollipop 3Health News:Global Med Technologies(R) Inc. to Announce Third Quarter Results On October 30th - Conference Call to Follow Release 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: